Cabaletta Bio outlines 2026 strategic priorities for autoimmune therapy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Cabaletta Bio Announces 2026 Strategic Priorities
January 12, 2026 8:00 AM ESTRegistrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission including an outpatient dosing option using a single weight-based doseÂ
IND amendment cleared to manufacture rese-cel with the automated, scalable Cellares platform based on multiple successful engineering runs; clinical manufacturing data expected in 1H26 to confirm GMP readiness, including supply chain logistics
New durability data without preconditioning and higher dose initial clinical data from RESET-PV expected in 1H26; dose-ranging data from RESET-SLE without preconditioning anticipated in 2026
Complete Phase 1/2 data anticipated in... More
